Biogen Inks $1b Deal for Chinese Startups’ BTK Inhibitor Targeting Multiple Sclerosis

Biogen Inks $1b Deal for Chinese Startups’ BTK Inhibitor Targeting Multiple Sclerosis

In a deal worth nearly $1 billion if all milestones are met, one of the world’s largest biotech companies, Cambridge, MA-based Biogen Inc. (Nasdaq: BIIB) licensed an oral small molecule Bruton’s tyrosine kinase inhibitor (BTKi) from a startup from China called InnoCare Pharma Limited (HKEX: 09969). Called Orelabrutinib, the Chinese venture has focused to date on research targeting multiple sclerosis (MS). A covalent BTKi with high selectivity and the ability to cross the blood-brain barrier, Orelabrutinib has now entered a multi-country, placebo-controlled Phase 2 clinical trial in relapsing-remitting MS. Based on this deal, Biogen secures exclusive, worldwide rights to the investigational product along with rights to target select autoimmune diseases outside of China (including Hong Kong, Macau, and Taiwan). InnoCare secures a $125 million upfront payment along with the retention of exclusive worldwide rights to the drug in the field of oncology and select autoimmune diseases in China (including Hong Kong, Macau, and Taiwan). 

TrialSite’s InvestorWatch offers a brief deal breakdown summary.

What is the flagship investigational product associated with InnoCare?


Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee